Literature DB >> 57828

Uridine 5'-diphosphate-galactose:glycoprotein galactosyltransferase activity in the ovarian cancer patient.

M Bhattacharya, S K Chatterjee, J J Barlow.   

Abstract

Uridine 5'-diphosphate-galactose:glycoprotein galactosyltransferase activity was demonstrated in homogenates of normal ovary and ovarian epithelial adenocarcinomas. The specific activity of the enzyme in ovarian tumors was 3 to 5 times higher than in normal ovaries when the enzyme was assayed under identical conditions. The glycoprotein fetuin, from which terminal sialic acid and penultimate galactose were removed (fetuin minus N-acetylneuraminis acid and galactose), acted as an excellent exogenous acceptor. Galactosyltransferase from normal ovary and ovarian tumor cells had similar properties. Both required Mn2+ and Triton X-100 and had broad pH optima between 5.5 and 7. Galactosyltransferase activity was also measured in serum samples from ovarian cancer patients and normal healthy individuals in the presence of fetuin minus N-acetylneuraminic acid and galactose as exogenous acceptor. The enzyme levels were significantly elevated in the sera of ovarian cancer patients as compared to normal controls. The differences in the levels of this enzyme in the tissues and sera of normal individuals and ovarian cancer patients were not due to differential levels of the degrading enzymes such as uridine 5'-diphosphate-galactose pyrophosphatase or beta-D-galactosidase. Serial determinations were carried out on the sera of 5 ovarian cancer patients over a long period of time. The serum level of galactosyltransferase activity appeared to correlate with tumor volume as well as with the clinical status of the patient, which suggests possible leakage of the tumor enzyme into the host sera. Serial determination of this enzyme level in ovarian cancer patients seems promising in measuring tumor progression or success of therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 57828

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  [Glycoproteins: their biological and clinical significance. II (author's transl)].

Authors:  E Köttgen; C Bauer; W Reutter; W Gerok
Journal:  Klin Wochenschr       Date:  1979-03-01

Review 2.  The structural relationship of blood group-related oligosaccharides in human carcinoma to biological function: a perspective.

Authors:  V E Dube
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

3.  Purification of membrane-bound galactosyltransferase from rat liver microsomal fractions.

Authors:  I H Fraser; S Mookerjea
Journal:  Biochem J       Date:  1977-06-15       Impact factor: 3.857

4.  Activity of antibodies recovered from immune complexes of ovarian cancer patients.

Authors:  P M Lutz; J R Dawson
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

5.  Characterization of monoclonal antibodies to serum galactosyltransferase.

Authors:  D K Podolsky; K J Isselbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

6.  Changes in normal glycosylation mechanisms in autoimmune rheumatic disease.

Authors:  J S Axford; N Sumar; A Alavi; D A Isenberg; A Young; K B Bodman; I M Roitt
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

7.  Serum galactosyltransferase isoenzyme patterns of cancer patients with liver involvement.

Authors:  R Davey; R Harvie; J Cahill; J Levi
Journal:  Br J Cancer       Date:  1986-02       Impact factor: 7.640

8.  Abnormal expression of blood group-related antigens in uterine endometrial cancers.

Authors:  K Tsukazaki; M Sakayori; H Arai; K Yamaoka; S Kurihara; S Nozawa
Journal:  Jpn J Cancer Res       Date:  1991-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.